Sign in
Taking peoplePhase 2

FG001 imaging agent to help locate meningioma or low-grade glioma during brain surgery

Tests FG001, an imaging agent, in adults with meningioma or suspected low-grade glioma.

Key facts

Who runs it
Copenhagen University Hospital
Where
Denmark1 site in 1 countryChoose a country to see its sites
Registry title
FG001 in subjects with Meningiomas or presumed Low-Grade Gliomas scheduled for neurosurgery.
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
29 Jan 2025
Planned end
1 Jun 2026
Type of study
Interventional
Record updated
11 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose MRI scan suggests a meningioma or a presumed low-grade glioma, a brain tumour. They must have brain surgery planned to remove the tumour. The trial tests FG001, a dye that helps doctors see the tumour.

Age
18 years or older
Sex
All sexes
Disease stage
A primary brain tumour on MRI that looks like a primary meningioma or a presumed low-grade glioma. Brain surgery to remove the tumour must be planned. People must be fit enough for surgery by the hospital's usual standards.
Earlier treatment
People cannot join if they have had FG001 before.
Biomarker or test result
Normal organ and bone marrow function is needed.

Main reasons for not taking part

  • Known allergy to indocyanine green (ICG)
  • Pregnant, or breastfeeding and not willing to pause breastfeeding during the trial and for 30 days
  • Liver or kidney problems (INR > 1,7, or eGFR <45 ml/min/1,73m2)
  • General health or other illnesses that make taking part unsafe, as judged by the trial doctor
  • Unwilling or unable to follow the trial rules

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Subjects diagnosed with primary brain tumor on MRI suggestive of primary meningioma or presumed low-grade glioma (pLGG)
  • Scheduled for neurosurgery with the objective to remove cancer tissue
  • Subjects aged 18 years or older
  • Capable of understanding and giving written informed consent
  • Women of childbearing potential must agree to use an adequate method of contraception during the trial and for 30 days after the end-of-trial visit. Adequate methods of contraception include intrauterine device or hormonal contraception (oral contraceptive pill, depot injections or implant, transdermal depot patch or vaginal ring). To be considered sterilised or infertile, females must have undergone surgical sterilisation (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be post-menopausal (defined as at least 12 months amenorrhoea; may be confirmed with follicle-stimulating hormone [FSH] test if there is doubt)
  • Male subjects must commit to use barrier contraception (e.g., condom) during the trial and for 30 days after the end-of-trial visit
  • Subject must not previously have received the trial drug (FG001)
  • Subjects must have normal organ and bone marrow function and be appropriate surgical candidates per site standard of care (SOC)

Who cannot take part

  • Female subjects who are pregnant or breast-feeding (pregnancy test positive prior to inclusion (or if breast- feeding willing to pause breast feeding during trial and for 30 days
  • Any known allergy or hypersensitivity to indocyanine green (ICG)
  • Pre-existing hepatic and/or renal insufficiency (INR > 1,7, Estimated GFR (eGFR) <45 ml/min/1,73m2)
  • Overall performance status or co-morbidity deeming the subject unfitted for participation in the trial as judged by the Investigator
  • Unwilling or unable to follow the protocol requirements

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate FG001 for the detection of meningioma, or presumed low-grade glioma (pLGG).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
An open-label, non-randomized, single dose, phase II trial of FG001 (an optical imaging agent) for localization of Meningiomas or presumed Low- Grade Gliomas scheduled for neurosurgery.
Plain-language title
FG001 imaging agent to help locate meningioma or low-grade glioma during brain surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 November 2026